Mannatech Reports Third Quarter End 2022 Financial Results
08 Nov 2022
Financial StatementVaccine
FLOWER MOUND, Texas--(BUSINESS WIRE)--Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2022.
Third Quarter End Results
Third quarter net sales for 2022 were $35.5 million, a decrease of $3.9 million, or 10.0%, as compared to $39.4 million in the third quarter of 2021. Our net sales declined 1.3% on a constant dollar basis (see Non-GAAP Measures, below) as foreign exchange decreased GAAP net sales by $3.4 million, mostly due to the decline of the Korean Won and Japanese Yen.
Third quarter operating income for 2022 was $1.4 million as compared to $3.3 million for the third quarter of 2021.
Net income was $1.2 million, or $0.61 per diluted share, for the third quarter of 2022, as compared to net income of $2.9 million, or $1.44 per diluted share, for the third quarter of 2021.
For the three months ended September 30, 2022, overall selling and administrative expenses decreased by $0.5 million to $6.7 million, as compared to $7.2 million for the same period in 2021. The decrease in selling and administrative expenses consisted of a $0.7 million decrease in payroll costs, and a $0.1 million decrease in warehouse costs, which was partially offset by a $0.3 million increase in marketing costs.
For the three months ended September 30, 2022, other operating costs increased by $0.1 million to $5.1 million, as compared to $5.0 million for the same period in 2021. The increase in operating costs was primarily due to a $0.1 million increase in travel and entertainment.
The approximate number of new and continuing independent associate and preferred customer positions held by individuals in Mannatech’s network and associated with purchases of products as of September 30, 2022 and 2021 were approximately 150,000 and 166,000, respectively. Recruitment of new independent associates and preferred customers decreased by 23.0% to 19,273 in the third quarter of 2022 as compared to 25,036 in the third quarter of 2021.
Year-to-date Third Quarter Results
For the nine months ended September 30, 2022, net sales were $102.9 million, a decrease of $17.4 million, or 14.5%, as compared to $120.3 million for the same period in 2021. Our net sales declined 8.2% on a constant dollar basis (see Non-GAAP Measures, below) as foreign exchange decreased GAAP net sales by $7.5 million mostly due to the decline of the Korean Won and Japanese Yen. Income from operations decreased to $2.2 million for the nine months ended September 30, 2022, from $8.1 million in the same period in 2021.
Net income was $2.0 million, or $1.01 per diluted share, for the nine months ended September 30, 2022, as compared to net income of $7.3 million, or $3.47 per diluted share, for the same period in 2021.
Non-GAAP Measures
In addition to results presented in accordance with GAAP, this press release and related tables include certain non-GAAP financial measures, including a presentation of constant dollar measures. We disclose operating results that have been adjusted to exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, including changes in: Net Sales, Gross Profit, and Income from Operations. We believe that these non-GAAP financial measures provide useful information to investors because they are an indicator of the strength and performance of ongoing business operations. The constant currency figures are financial measures used by management to provide investors an additional perspective on trends. Although we believe the non-GAAP financial measures enhance investors’ understanding of our business and performance, these non-GAAP financial measures should not be considered an exclusive alternative to accompanying GAAP financial measures. Please see the accompanying table entitled "Non-GAAP Financial Measures" for a reconciliation of these non-GAAP financial measures.
Safe Harbor statement
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as “may,” “will,” “should,” “hope,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “approximates,” “predicts,” “projects,” “potential,” and “continues” or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, the impact of COVID-19 on Mannatech’s business, the availability and effectiveness of vaccines on a widespread basis, the impact of any mutations of the COVID-19 virus, the current conflict between Russia and Ukraine, which could adversely affect our business in certain regions, the impact of inflation, disruptions in the supply chain, Mannatech's inability to attract and retain associates and preferred customers, increases in competition, litigation, regulatory changes, and its planned growth into new international markets. Although Mannatech believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.
Individuals interested in Mannatech's products or in exploring its business opportunity can learn more at Mannatech.com
MANNATECH, INCORPORATED AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except share information)
ASSETS
September 30,
2022
(unaudited)
December 31,
2021
Cash and cash equivalents
$
15,092
$
24,185
Restricted cash
944
944
Accounts receivable, net of allowance of $899 and $987 in 2022 and 2021, respectively
270
90
Income tax receivable
368
342
Inventories, net
15,251
12,020
Prepaid expenses and other current assets
1,943
2,888
Deferred commissions
2,574
2,369
Total current assets
36,442
42,838
Property and equipment, net
3,613
2,882
Construction in progress
283
1,357
Long-term restricted cash
435
503
Other assets
8,757
9,220
Deferred tax assets, net
2,970
2,825
Total assets
$
52,500
$
59,625
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current portion of finance leases
$
65
$
68
Accounts payable
4,581
3,969
Accrued expenses
7,504
9,224
Commissions and incentives payable
8,402
9,611
Taxes payable
1,908
2,154
Current notes payable
323
205
Deferred revenue
5,952
4,867
Total current liabilities
28,735
30,098
Finance leases, excluding current portion
102
66
Deferred tax liabilities
—
—
Long-term notes payable
—
—
Other long-term liabilities
5,052
5,049
Total liabilities
33,889
35,213
Commitments and contingencies
Shareholders’ equity:
Preferred stock, $0.01 par value, 1,000,000 shares authorized, no shares issued or outstanding
—
—
Common stock, $0.0001 par value, 99,000,000 shares authorized, 2,742,857 shares issued and 1,874,930 shares outstanding as of September 30, 2022 and 2,742,857 shares issued and 1,940,687 shares outstanding as of December 31, 2021
—
—
Additional paid-in capital
33,418
33,277
Retained earnings
8,567
7,708
Accumulated other comprehensive (loss) income
(3,053
)
2,342
Treasury stock, at average cost, 867,927 shares as of September 30, 2022 and 802,170 shares as of December 31, 2021
(20,321
)
(18,915
)
Total shareholders’ equity
18,611
24,412
Total liabilities and shareholders’ equity
$
52,500
$
59,625
MANNATECH, INCORPORATED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share information)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2022
2021
2022
2021
Net sales
$
35,513
$
39,446
$
102,873
$
120,269
Cost of sales
7,416
7,903
22,427
25,251
Gross profit
28,097
31,543
80,446
95,018
Operating expenses:
Commissions and incentives
14,242
15,731
41,487
48,227
Selling and administrative expenses
6,656
7,156
20,479
21,838
Depreciation and amortization expense
716
408
1,349
1,360
Other operating costs
5,126
4,962
14,886
15,500
Total operating expenses
26,740
28,257
78,201
86,925
Income from operations
1,357
3,286
2,245
8,093
Interest income, net
19
15
57
44
Other income (expense), net
287
(19
)
288
(149
)
Income before income taxes
1,663
3,282
2,590
7,988
Income tax (provision)
(472
)
(352
)
(571
)
(735
)
Net income
$
1,191
$
2,930
$
2,019
$
7,253
Earnings per common share:
Basic
$
0.62
$
1.54
$
1.05
$
3.63
Diluted
$
0.61
$
1.44
$
1.01
$
3.47
Weighted-average common shares outstanding:
Basic
1,906
1,903
1,932
2,010
Diluted
1,949
2,031
2,017
2,095
Non-GAAP Financial Measures (Sales, Gross Profit and Income from Operations in Constant Dollars)
To supplement our financial results presented in accordance with generally accepted accounting principles in the United States (“GAAP”), we disclose operating results that have been adjusted to exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, including changes in: Net Sales, Gross Profit, and Income from Operations. We refer to these adjusted financial measures as constant dollar items, which are non-GAAP financial measures. We believe these measures provide investors an additional perspective on trends. To exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, we calculate current year results and prior year results at a constant exchange rate, which is the prior year’s rate. Currency impact is determined as the difference between actual growth rates and constant currency growth rates.
The table below reconciles third quarter 2022 and year-to-date constant dollar net sales, gross profit and income from operations to our GAAP net sales, gross profit and income from operations.
Three-month period ended (in millions, except percentages)
September 30, 2022
September 30,
2021
Constant $ Change
GAAP
Measure:
Total $
Non-GAAP
Measure:
Constant $
GAAP
Measure:
Total $
Dollar
Percent
Net sales
$
35.5
$
38.9
$
39.4
$
(0.5
)
(1.3
)%
Product
33.6
36.8
36.9
(0.1
)
(0.3
)%
Pack sales and associate fees
1.7
1.9
2.4
(0.5
)
(20.8
)%
Other
0.2
0.2
0.1
0.1
100.0
%
Gross profit
28.1
30.9
31.5
(0.6
)
(1.9
)%
Income from operations
1.4
2.2
3.3
(1.1
)
(33.3
)%
Nine-month period ended (in millions, except percentages)
September 30, 2022
September 30,
2021
Constant $ Change
GAAP
Measure:
Total $
Non-GAAP
Measure:
Constant $
GAAP
Measure:
Total $
Dollar
Percent
Net sales
$
102.9
$
110.4
$
120.3
$
(9.9
)
(8.2
)%
Product
97.5
104.5
113.2
(8.7
)
(7.7
)%
Pack sales and associate fees
4.8
5.3
6.5
(1.2
)
(18.5
)%
Other
0.6
0.7
0.6
0.1
16.7
%
Gross profit
80.4
86.7
95.0
(8.3
)
(8.7
)%
Income from operations
2.2
4.1
8.1
(4.0
)
(49.4
)%
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.